EphA2 gene silencing has been shown to result in antitumor efficacy. Here we considered whether silencing additional targets downstream of EphA2 would further enhance the
therapeutic effect. EphA2 targeted
siRNA was tested in combination with either FAK or Src targeted
siRNA using
DOPC nanoliposomes in orthotopic models of ovarian
carcinoma. The effects of
therapy were determined by changes in
tumor weight, proliferation (Ki-67), and microvessel density (CD31). In our initial in vivo study, EphA2 plus FAK silencing resulted in the greatest reduction in
tumor growth (by 73%, p < 0.005) as compared to control
siRNA alone. In the SKOV3ip1 and HeyA8
ovarian cancer models, EphA2
siRNA-
DOPC treatment resulted in a 50-67% decrease in
tumor growth (p < 0.02, for both), and FAK
siRNA-
DOPC resulted in a 61-62% decrease in
tumor growth (p < 0.009, p < 0.05, respectively). EphA2 plus FAK
siRNA-
DOPC treatment resulted in a significant reduction (SKOV3ip1: 76%, p < 0.007, HeyA8: 90%, p < 0.003) in
tumor growth compared to control
siRNA-
DOPC. Combination treatment with EphA2 + FAK
siRNA-
DOPC resulted in significant decreases in
tumor cell proliferation (p < 0.001) and microvessel density compared to control
siRNA-
DOPC (80%; p < 0.001), or the monotherapy groups (p values <0.001). These data suggest that the antitumor efficacy of in vivo EphA2 targeting is enhanced in combination with FAK silencing. Dual targeting of EphA2 and FAK may have therapeutic implications for
ovarian cancer management.